Secondary hyperparathyroidism (SHPT) is often observed in patients with end-stage renal disease (ESRD) and can result in excessive parathyroid hormone (PTH) secretion, leading to osteodystrophy, bone fractures, and increased risks of mortality and cardiovascular events (1–4). The gene discussed is PTH; the disease is chronic kidney disease.